EE03031B1 - Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid - Google Patents

Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid

Info

Publication number
EE03031B1
EE03031B1 EE9400328A EE9400328A EE03031B1 EE 03031 B1 EE03031 B1 EE 03031B1 EE 9400328 A EE9400328 A EE 9400328A EE 9400328 A EE9400328 A EE 9400328A EE 03031 B1 EE03031 B1 EE 03031B1
Authority
EE
Estonia
Prior art keywords
antigen
monoclonal antibody
carbogen
tumor
pharmaceutical compositions
Prior art date
Application number
EE9400328A
Other languages
English (en)
Estonian (et)
Inventor
Lindholm Leif
Holmgren Jan
Lind Peter
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of EE03031B1 publication Critical patent/EE03031B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EE9400328A 1991-07-03 1994-11-16 Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid EE03031B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9102074A SE9102074D0 (sv) 1991-07-03 1991-07-03 Tomour antigen specific antibody

Publications (1)

Publication Number Publication Date
EE03031B1 true EE03031B1 (et) 1997-08-15

Family

ID=20383243

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9400328A EE03031B1 (et) 1991-07-03 1994-11-16 Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid

Country Status (19)

Country Link
US (1) US5552293A (sv)
EP (1) EP0521842B1 (sv)
JP (1) JP3194020B2 (sv)
KR (1) KR100246681B1 (sv)
AT (1) ATE171193T1 (sv)
AU (2) AU2292092A (sv)
CA (1) CA2073124C (sv)
DE (1) DE69226990T2 (sv)
DK (1) DK0521842T3 (sv)
EE (1) EE03031B1 (sv)
ES (1) ES2124250T3 (sv)
FI (1) FI109207B (sv)
HU (2) HU218084B (sv)
IE (1) IE80841B1 (sv)
IL (1) IL102390A (sv)
NO (1) NO315472B1 (sv)
NZ (1) NZ243435A (sv)
SE (1) SE9102074D0 (sv)
WO (2) WO1993001302A1 (sv)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402430L (sv) 1994-07-11 1996-01-12 Pharmacia Ab Konjugat mellan modifierat superantigen och en målsökande förening samt användning av konjugaten
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
EP1411962B1 (en) * 2001-03-15 2011-01-19 Neogenix Oncology, Inc. Monoclonal antibody therapy for pancreas cancer
DE10116552A1 (de) * 2001-04-03 2002-10-10 Abc Armbruster Biochemicals Verfahren zur Bestimmung der wirksamen Parathormon-Aktivität in einer Probe
US20060246060A1 (en) * 2002-07-02 2006-11-02 Nesta Douglas P Novel stable formulation
US7390898B2 (en) 2002-08-02 2008-06-24 Immunogen Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
DK1651162T3 (en) 2003-05-20 2016-02-01 Immunogen Inc IMPROVED CYTOTOXIC AGENTS WITH NEW MAYTANSINOIDS
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US20060182750A1 (en) * 2005-02-11 2006-08-17 Immunogen, Inc. Process for preparing stable drug conjugates
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
NZ595386A (en) * 2005-08-11 2013-08-30 Arpi Matossian Rogers Peptides for treatment and diagnosis of autoimmune disease
EP1928503B1 (en) 2005-08-24 2012-10-03 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
KR20160039295A (ko) 2008-08-05 2016-04-08 도레이 카부시키가이샤 암의 검출 방법
PL2437790T3 (pl) 2009-06-03 2019-09-30 Immunogen, Inc. Sposoby sprzęgania
KR20220123130A (ko) 2011-03-29 2022-09-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
WO2012135517A2 (en) 2011-03-29 2012-10-04 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
EP3220959A1 (en) 2014-11-19 2017-09-27 ImmunoGen, Inc. Process for preparing cell-binding agent-cytotoxic agent conjugates
KR20180100412A (ko) 2016-01-10 2018-09-10 네오티엑스 테라퓨틱스 엘티디. 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
RU2018130108A (ru) 2016-02-05 2020-03-06 Иммуноджен, Инк. Эффективный способ получения конъюгатов связывающийся с клеткой агент цитотоксический агент
CN107167590B (zh) * 2017-04-14 2019-03-08 江苏福隆生物技术有限公司 糖类抗原242的板式化学发光法检测试剂盒及制备方法
US20200256880A1 (en) * 2017-08-16 2020-08-13 The Broad Institute, Inc. Neuronal Assay Method Involving Calcineurin
AU2020275142A1 (en) 2019-05-15 2021-12-16 Neotx Therapeutics Ltd. Cancer treatment
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752569A (en) * 1984-06-21 1988-06-21 The Regents Of The University Of California Sialylated Lewisx epitope, antibodies and diagnosis
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
SE8902043L (sv) * 1988-11-10 1990-05-11 Pharmacia Ab Foerfarande foer karakterisering av makromolekyler
JPH06500077A (ja) * 1990-07-20 1994-01-06 カビ・フアーマシア・アクチエボラーグ 接合体物質、試薬および新規なポリエーテル
ES2094231T3 (es) * 1990-07-20 1997-01-16 Pharmacia & Upjohn Ab Conjugados de anticuerpos superantigenos especificos de una diana y su preparacion.

Also Published As

Publication number Publication date
ES2124250T3 (es) 1999-02-01
WO1993001303A1 (en) 1993-01-21
CA2073124A1 (en) 1993-01-04
NO934777L (no) 1994-02-11
KR100246681B1 (ko) 2000-04-01
US5552293A (en) 1996-09-03
EP0521842A3 (sv) 1994-01-26
HU9400011D0 (en) 1994-05-30
NO934777D0 (no) 1993-12-22
ATE171193T1 (de) 1998-10-15
CA2073124C (en) 2007-06-19
HU211512A9 (en) 1995-11-28
SE9102074D0 (sv) 1991-07-03
IE922188A1 (en) 1993-01-13
DK0521842T3 (da) 1999-06-14
JPH05276987A (ja) 1993-10-26
IL102390A (en) 1996-01-19
EP0521842B1 (en) 1998-09-16
AU658198B2 (en) 1995-04-06
JP3194020B2 (ja) 2001-07-30
DE69226990T2 (de) 1999-03-25
FI935970A (fi) 1993-12-31
HU218084B (hu) 2000-05-28
FI935970A0 (fi) 1993-12-31
DE69226990D1 (de) 1998-10-22
HUT71193A (en) 1995-11-28
NO315472B1 (no) 2003-09-08
WO1993001302A1 (en) 1993-01-21
NZ243435A (en) 1994-10-26
IE80841B1 (en) 1999-03-24
IL102390A0 (en) 1993-01-14
EP0521842A2 (en) 1993-01-07
AU1942592A (en) 1993-01-07
FI109207B (sv) 2002-06-14
AU2292092A (en) 1993-02-11

Similar Documents

Publication Publication Date Title
EE03031B1 (et) Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid
FI101937B1 (sv) Förfarande för framställning av monoklonal antikropp reaktiva med human cachectin
ATE13317T1 (de) Hybridzellinie zur herstellung monoklonaler antikoerper gegen ein menschliches prothymozytantigen; antikoerper und verfahren zu seiner herstellung; diagnostische und therapeutische verwendungen und diesen antikoerper enthaltende pharmazeutische zusammensetzungen.
EP0822830A4 (en) HUMAN ANTIBODIES FROM IMMUNIZED XENOMAS
AU2097692A (en) Method for the production of monoclonal antibodies utilizing a germfree animal
GR3020108T3 (en) Monoclonal antibody reactive with a novel HLA determinant on MHC class I molecules and method for activating lymphocytes
JPS6447378A (en) Monoclonal antibody to black tumor related antigen, hybrid cell line for producing the same and use thereof
ATE113845T1 (de) Monoklonale antikörper gegen glycolipid-antigene und ihre verwendung.
TR199800607T1 (xx) Dendritik h�cre uyar�c� fakt�r�.
IL74156A (en) Method for the preparation of a monoclonal antibody and of an immortalized cell producing the same and pharmaceutical compositions containing the monoclonal antibody
DE69127487D1 (de) Verfahren zum Nachweis der Alzheimer-Krankheit
JPS5726623A (en) Vaccine and manufacture
PT81093A (de) Tumortherapeutikum und verfahren zu seiner herstellung
ATE116004T1 (de) Antikörper gegen menschliches sperma, ihre herstellung und anwendung.
DE3688204D1 (de) Monoklonaler antikoerper gegen ein p21-bezuegliches dodekapeptid des ras-onkogens.
ATE103989T1 (de) Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung.
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
AU2484488A (en) Method for the production of antigenic protein-hapten conjugates, and antibodies corresponding thereto
BG51640A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenous determinant, common for the strains " hantaan " and " bulgarian " of the virus of haemorrhagic fever with nephritic syndrome
BG51731A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenic deternimant, common for the strains hantaan and finnish of the virus of haemorrhagic fever with nephritic syndrome
DK182188A (da) Humant tumorassocieret antigen
IT8020164A0 (it) Procedimento per produrre colture sporifere di un ceppo di clavicepspurpurea virulento sulla segale e producente l'ergocristina.
BG51639A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody towards antigenous determinant of strain " hantaan " of the virus of haemorrhagic fever with nephritic syndrome

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

MM4A Lapsed by not paying the annual fees

Effective date: 20071116